<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734355</url>
  </required_header>
  <id_info>
    <org_study_id>0546-2015-0013</org_study_id>
    <nct_id>NCT02734355</nct_id>
  </id_info>
  <brief_title>Left Atrial Mechanical Function Improvement After Atrial Fibrillation Catheter Ablation</brief_title>
  <official_title>Upstream-therapy by Telmisartan and Amlodipine Combination for Improvement of Left Atrial Mechanical Function After Pulmonary Vein Antrum Isolation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Institute for Complex Problems of Cardiovascular Diseases, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Research Institute for Complex Problems of Cardiovascular Diseases, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study was to estimate the efficacy of telmisartan and amlodipine
      combination on the restoration of left atrial mechanical function after atrial fibrillation
      catheter ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      64 candidates to atrial fibrillation ablation were included in the study. Patients were
      randomly assigned to telmisartan/amlodipine combination in dose 80/5 mg (group I, n=34) or
      placebo (group II, n=30) taking daily for up to one week. Echocardiography was performed
      before the procedure, immediately after it, and after a week of therapy. The six-minute walk
      test and SF-36 questionnaire results were evaluated a day before the procedure and after a
      week of the therapy. The left ventricular end-diastolic pressure was invasively measured
      after transseptal puncture and before left atrial sheath removal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Passive Emptying of Left Atrium</measure>
    <time_frame>7 days</time_frame>
    <description>Velocity time integral of transmitral flow during left ventricle early filling phase (VTI E, cm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Active Emptying of Left Atrium</measure>
    <time_frame>7 days</time_frame>
    <description>Velocity time integral of transmitral flow during atrial contraction (VTI A, cm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Atrial Reservoir Function</measure>
    <time_frame>7 days</time_frame>
    <description>Velocity time integral of transmitral flow (VTITMF, cm) during the whole diastole.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic Function</measure>
    <time_frame>7 days</time_frame>
    <description>E/A ratio of transmitral flow</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Isovolumic Relaxation</measure>
    <time_frame>7 days</time_frame>
    <description>Left ventricular isovolumic relaxation time (IVRT, ms).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Vein Flow Emptying</measure>
    <time_frame>7 days</time_frame>
    <description>S/D ratio of right superior pulmonary vein flow</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrograde Flow in Pulmonary Veins</measure>
    <time_frame>7 days</time_frame>
    <description>Velocity time integral of right superior pulmonary vein flow during left atrial systole (VTI Ar, cm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Atrial Contractility</measure>
    <time_frame>7 days</time_frame>
    <description>Left atrial active emptying fraction (LAAEF, %)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Atrial Dimensions</measure>
    <time_frame>7 days</time_frame>
    <description>Left atrial antero-posterior diameter (LAD, cm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Atrial Pressure Load</measure>
    <time_frame>7 days</time_frame>
    <description>Mean left atrial pressure (MLAP, mm Hg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Circulation Pressure Load</measure>
    <time_frame>7 days</time_frame>
    <description>Right ventricular systolic pressure (RVSP, mm Hg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>7 days</time_frame>
    <description>The average of eight scores of 36-Item Short Form Health Survey (SF-36). In every case all of eight scores (which ranges from 0 to 100) was summarized, then the sum was divided by 8. Thus the outcome also ranges from 0 (worse outcome) to 100 (better outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Tolerance</measure>
    <time_frame>7 days</time_frame>
    <description>six-minute walk distance in meters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80 mg and amlodipine 5 mg</intervention_name>
    <arm_group_label>Therapy</arm_group_label>
    <other_name>Twynsta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for telmisartan and amlodipine)</intervention_name>
    <description>Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic (III-IV class by European Heart Rhythm Association scale) paroxysmal
             atrial fibrillation;

          -  Ineffective therapy by at least one of the class I or III antiarrhythmic drugs;

          -  Left atrial diameter 5 cm or less;

          -  Estimated catheter radiofrequency pulmonary vein antrum isolation;

          -  Signed informed consent.

        Exclusion Criteria:

          -  Intolerance/allergy or contraindications to telmisartan, amlodipine, warfarin or
             enoxaparin;

          -  Left atrial thrombosis;

          -  Age greater than 75 years;

          -  Severe (e.g. decompensation of vital functions) or acute (e.g. pneumonia) somatic
             conditions;

          -  Malignant growth in the hematogenic dissemination stage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yevgeny V Grigoriev, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Research Institute for Complex Problems of Cardiovascular Diseases</affiliation>
  </overall_official>
  <reference>
    <citation>Mamchur S, Mamchur I, Khomenko E, Kokov A, Bokhan N, Sherbinina D. Mechanical function of left atrium and pulmonary vein sleeves before and after their antrum isolation. Medicina (Kaunas). 2014;50(6):353-9. doi: 10.1016/j.medici.2014.11.008. Epub 2014 Nov 28.</citation>
    <PMID>25541269</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <results_first_submitted>October 13, 2016</results_first_submitted>
  <results_first_submitted_qc>February 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 22, 2017</results_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Research Institute for Complex Problems of Cardiovascular Diseases, Russia</investigator_affiliation>
    <investigator_full_name>Sergey Mamchur</investigator_full_name>
    <investigator_title>Head of Department of Cardiovascular Disorders Diagnosis</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>left atrium</keyword>
  <keyword>mechanical function</keyword>
  <keyword>contractility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Therapy</title>
          <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Therapy</title>
          <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days
Telmisartan 80 mg and amlodipine 5 mg</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days
Placebo (for telmisartan and amlodipine): Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="5.7"/>
                    <measurement group_id="B2" value="54.1" spread="6.2"/>
                    <measurement group_id="B3" value="53.1" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Passive Emptying of Left Atrium</title>
        <description>Velocity time integral of transmitral flow during left ventricle early filling phase (VTI E, cm).</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Passive Emptying of Left Atrium</title>
          <description>Velocity time integral of transmitral flow during left ventricle early filling phase (VTI E, cm).</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="4.4"/>
                    <measurement group_id="O2" value="20.9" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Active Emptying of Left Atrium</title>
        <description>Velocity time integral of transmitral flow during atrial contraction (VTI A, cm).</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Active Emptying of Left Atrium</title>
          <description>Velocity time integral of transmitral flow during atrial contraction (VTI A, cm).</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="2.6"/>
                    <measurement group_id="O2" value="5.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Atrial Reservoir Function</title>
        <description>Velocity time integral of transmitral flow (VTITMF, cm) during the whole diastole.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Left Atrial Reservoir Function</title>
          <description>Velocity time integral of transmitral flow (VTITMF, cm) during the whole diastole.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="3.5"/>
                    <measurement group_id="O2" value="13.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diastolic Function</title>
        <description>E/A ratio of transmitral flow</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Function</title>
          <description>E/A ratio of transmitral flow</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.35"/>
                    <measurement group_id="O2" value="2.64" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Isovolumic Relaxation</title>
        <description>Left ventricular isovolumic relaxation time (IVRT, ms).</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Isovolumic Relaxation</title>
          <description>Left ventricular isovolumic relaxation time (IVRT, ms).</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" spread="19"/>
                    <measurement group_id="O2" value="98" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Vein Flow Emptying</title>
        <description>S/D ratio of right superior pulmonary vein flow</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Vein Flow Emptying</title>
          <description>S/D ratio of right superior pulmonary vein flow</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.39"/>
                    <measurement group_id="O2" value="1.46" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Retrograde Flow in Pulmonary Veins</title>
        <description>Velocity time integral of right superior pulmonary vein flow during left atrial systole (VTI Ar, cm)</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Retrograde Flow in Pulmonary Veins</title>
          <description>Velocity time integral of right superior pulmonary vein flow during left atrial systole (VTI Ar, cm)</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.4"/>
                    <measurement group_id="O2" value="1.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Atrial Contractility</title>
        <description>Left atrial active emptying fraction (LAAEF, %)</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Left Atrial Contractility</title>
          <description>Left atrial active emptying fraction (LAAEF, %)</description>
          <units>percentage of LA maximum volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" spread="6.7"/>
                    <measurement group_id="O2" value="31.6" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Atrial Dimensions</title>
        <description>Left atrial antero-posterior diameter (LAD, cm)</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Left Atrial Dimensions</title>
          <description>Left atrial antero-posterior diameter (LAD, cm)</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="0.3"/>
                    <measurement group_id="O2" value="4.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Atrial Pressure Load</title>
        <description>Mean left atrial pressure (MLAP, mm Hg).</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Left Atrial Pressure Load</title>
          <description>Mean left atrial pressure (MLAP, mm Hg).</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="3.1"/>
                    <measurement group_id="O2" value="13.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Circulation Pressure Load</title>
        <description>Right ventricular systolic pressure (RVSP, mm Hg).</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Circulation Pressure Load</title>
          <description>Right ventricular systolic pressure (RVSP, mm Hg).</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="9.6"/>
                    <measurement group_id="O2" value="31.6" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>The average of eight scores of 36-Item Short Form Health Survey (SF-36). In every case all of eight scores (which ranges from 0 to 100) was summarized, then the sum was divided by 8. Thus the outcome also ranges from 0 (worse outcome) to 100 (better outcome).</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>The average of eight scores of 36-Item Short Form Health Survey (SF-36). In every case all of eight scores (which ranges from 0 to 100) was summarized, then the sum was divided by 8. Thus the outcome also ranges from 0 (worse outcome) to 100 (better outcome).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" spread="4"/>
                    <measurement group_id="O2" value="85" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Tolerance</title>
        <description>six-minute walk distance in meters</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Tolerance</title>
          <description>six-minute walk distance in meters</description>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403" spread="27"/>
                    <measurement group_id="O2" value="345" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Therapy</title>
          <description>Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling of lower leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Drug-induced hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sergey Mamchur</name_or_title>
      <organization>Research Institute for Complex Problems of Cardiovascular Diseases, Russia</organization>
      <phone>+73842643308</phone>
      <email>reception@kemcardio.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

